ACR-ACNM-ASTRO-SNMMI 镥-177 DOTATATE 治疗实践参数
该实践参数由美国放射学会(ACR)两个实践参数委员会牵头,联合美国核医学学会、美国放射肿瘤学会和核医学与分子影像学会制定,旨在指导授权使用者筛选适合接受镥-177 DOTATATE 肽受体放射性核素治疗(PRRT)的成人胃肠胰神经内分泌肿瘤(GEP-NET)患者,并规范药物安全操作、患者管理、治疗后监测及辐射安全指导。
要点
- 适用对象为生长抑素受体阳性的前肠、中肠、后肠来源胃肠胰神经内分泌肿瘤,通常无法手术且标准治疗失败。
- 镥-177 DOTATATE 对肿瘤过表达的生长抑素受体具有高亲和力,可缩小肿瘤、改善症状并延长无进展生存期。
- 实践参数涵盖药理学、适应证、不良反应、人员资质、治疗前临床评估、治疗后监测、质量保证及书面辐射安全指导。
核心结论
- 镥-177 DOTATATE 可用于常规治疗失败后无法手术和/或晚期胃肠胰神经内分泌肿瘤的治疗,能缩小肿瘤、改善症状并延长无进展生存期。
- 该实践参数为授权使用者提供临床指导,以确保镥-177 DOTATATE 治疗适当、一致且安全。
研究设计与样本
- 实践参数由美国放射学会(ACR)两个实践参数委员会(核医学与分子影像、放射肿瘤)牵头,联合美国核医学学会、美国放射肿瘤学会和核医学与分子影像学会共同制定。
- 制定过程遵循美国放射学会(ACR)网站所述的系统流程。
主要发现
- 文件回顾了镥-177 DOTATATE 的药理学、适应证、不良反应、人员资质、治疗前所需临床评估、推荐的治疗后监测、质量保证、文档记录及以书面形式提供并向患者解释的适当辐射安全指导。
- 基本筛选标准包括生长抑素受体阳性的胃肠胰神经内分泌肿瘤,通常无法手术且尽管接受标准治疗仍进展。
关键数值与推荐
- 适用成人患者为前肠、中肠和后肠来源的胃肠胰神经内分泌肿瘤。
- 选择标准为生长抑素受体阳性、通常无法手术且标准治疗失败的胃肠胰神经内分泌肿瘤。
- 镥-177 DOTATATE 是对肿瘤过表达的生长抑素受体具有高亲和力的放射性药物。
临床怎么用
- 授权使用者应依据该实践参数选择 appropriate 成人胃肠胰神经内分泌肿瘤患者接受镥-177 DOTATATE 治疗。
- 授权使用者应确保镥-177 DOTATATE 的安全操作及对受影响患者的安全管理。
- 应以书面形式向患者提供辐射安全指导并进行解释。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This practice parameter (PP) for Lutetium-177 (Lu-177) DOTATATE peptide receptor radionuclide therapy (PRRT) aims to guide authorized users in selection of appropriate adult candidates with gastroeneropancreatic neuroendocrine tumors (GEP-NETs) from foregut, midgut, and hindgut. The essential selection criteria include somatostatin receptor-positive GEP-NETs, which are usually inoperable and progressed despite standard therapy. Lu-177 DOTATATE is a radiopharmaceutical with high avidity for somatostatin receptors that are overexpressed by these tumors. This document ensures safe handling of Lu-177 DOTATATE by the authorized users and safe management of affected patients. METHODS: The document was developed according to the systematic process developed by the American College of Radiology (ACR) and described on the ACR Web site (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards). The PP development was led by 2 ACR Committees on Practice Parameters (Nuclear Medicine and Molecular Imaging and Radiation Oncology) collaboratively with the American College of Nuclear Medicine, American Society of Radiation Oncology, and Society of Nuclear Medicine and Molecular Imaging. RESULTS: The Lu-177 DOTATATE PP reviewed pharmacology, indications, adverse effects, personnel qualifications, and required clinical evaluation before starting the treatment, as well as the recommended posttherapy monitoring, quality assurance, documentation, and appropriate radiation safety instructions provided in written form and explained to the patients. CONCLUSIONS: Lu-177 DOTATATE is available for therapy of inoperable and/or advanced GEP-NETs when conventional therapy had failed. It can reduce tumor size, improve symptoms, and increase the progression free survival. The PP document provides clinical guidance for authorized users to assure an appropriate, consistent, and safe practice of Lu-177 DOTATATE.
引用
- Love C, Desai NB, Abraham T, et al. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Clin Nucl Med. 2022. PMID: 35507433. doi:10.1097/RLU.0000000000004182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。